KR20170090997A - Anti-fungal composition comprising lactobacillus plantarum - Google Patents
Anti-fungal composition comprising lactobacillus plantarum Download PDFInfo
- Publication number
- KR20170090997A KR20170090997A KR1020160182201A KR20160182201A KR20170090997A KR 20170090997 A KR20170090997 A KR 20170090997A KR 1020160182201 A KR1020160182201 A KR 1020160182201A KR 20160182201 A KR20160182201 A KR 20160182201A KR 20170090997 A KR20170090997 A KR 20170090997A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- lactobacillus plantarum
- culture
- weight
- plantarum apsulloc
- Prior art date
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 51
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 51
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 51
- 239000012871 anti-fungal composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 62
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims abstract description 17
- 208000008742 seborrheic dermatitis Diseases 0.000 claims abstract description 17
- 208000001840 Dandruff Diseases 0.000 claims abstract description 13
- 239000006166 lysate Substances 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 241001159568 Malassezia sp. Species 0.000 claims abstract description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 8
- 239000003429 antifungal agent Substances 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 241000555688 Malassezia furfur Species 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 3
- 241001291474 Malassezia globosa Species 0.000 claims description 2
- 241001291477 Malassezia restricta Species 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 abstract description 25
- 230000000843 anti-fungal effect Effects 0.000 abstract description 10
- 238000009472 formulation Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 244000269722 Thea sinensis Species 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 5
- 241000555676 Malassezia Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000006872 mrs medium Substances 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 229940113124 polysorbate 60 Drugs 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 235000013599 spices Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- 229920002498 Beta-glucan Polymers 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FXEDIXLHKQINFP-UHFFFAOYSA-N 12-O-tetradecanoylphorbol-13-acetate Natural products CCCCCCCCCCCCCC(=O)OC1CC2(O)C(C=C(CO)CC3(O)C2C=C(C)C3=O)C4C(C)(C)C14OC(=O)C FXEDIXLHKQINFP-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- OYINQIKIQCNQOX-UHFFFAOYSA-M 2-hydroxybutyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCC(O)C[N+](C)(C)C OYINQIKIQCNQOX-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- -1 Methacryloylethyl betaine Chemical compound 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- NGDHFSQTDSRVIB-UHFFFAOYSA-N dimethylazanium dichloride Chemical compound [Cl-].[Cl-].C[NH2+]C.C[NH2+]C NGDHFSQTDSRVIB-UHFFFAOYSA-N 0.000 description 1
- GLSRFBDXBWZNLH-UHFFFAOYSA-L disodium;2-chloroacetate;2-(4,5-dihydroimidazol-1-yl)ethanol;hydroxide Chemical compound [OH-].[Na+].[Na+].[O-]C(=O)CCl.OCCN1CCN=C1 GLSRFBDXBWZNLH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- BOUCRWJEKAGKKG-UHFFFAOYSA-N n-[3-(diethylaminomethyl)-4-hydroxyphenyl]acetamide Chemical compound CCN(CC)CC1=CC(NC(C)=O)=CC=C1O BOUCRWJEKAGKKG-UHFFFAOYSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940096501 sodium cocoamphoacetate Drugs 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
본 명세서에는 락토바실러스 플란타룸의 항진균 용도가 개시된다.The antifungal use of Lactobacillus plantarum is disclosed herein.
피부염(Dermatitis)은 피부에 발생하는 염증을 의미하며 보통 습진(Eczema)와 같은 의미로 사용된다. 피부염은 크게 아토피성 피부염(Atopic dermatitis), 접촉성 피부염(Contact dermatitis), 지루성 피부염(Seborrhoeic dermatitis)으로 구분된다. 지루성 피부염은 머리, 이마 또는 겨드랑이 등 피지의 분비가 많은 부위에 잘 발생하는데, 홍반과 가는 인설, 즉 비듬을 동반하고 때로는 마른버짐이 일기도 한다.Dermatitis is inflammation that occurs in the skin and is usually used in the same way as eczema. Dermatitis is largely divided into atopic dermatitis, contact dermatitis, and seborrhoeic dermatitis. Seborrheic dermatitis occurs in areas of the sebaceous glands, such as the head, forehead or armpit, which can be accompanied by erythema, dandruff and sometimes dry skin.
지루성 피부염 및 비듬의 원인으로 다양한 내인성 요인 및 외인성 요인 등이 알려져 있으나, 최근 진균, 즉 효모균이 가장 큰 영향력이 있는 요인으로 알려졌다. 따라서, 이들의 증식을 억제할 수 물질에 대한 연구가 활발하다. 현재 시중에서 항진균제로 케토코나졸(Ketoconazole), 아연 피리치온(Zinc pyrithion), 이트라코나졸(Itraconazole) 등의 합성물과 타르, 유황, 살리실산 등이 복합적으로 사용되고 있으나 인체안전성에 관한 의문이 끊임없이 제기되고 있다. 따라서, 인체에 무해하면서 지루성 피부염과 비듬을 억제할 수 있는 물질에 대한 연구가 필요한 실정이다.Various endogenous and exogenous factors are known to cause seborrheic dermatitis and dandruff. However, recently, it has been known that fungi, yeast, are the most influential factors. Therefore, researches on substances capable of inhibiting their proliferation are actively conducted. Currently, commercial anti-fungal agents such as ketoconazole, zinc pyrithione, itraconazole, tar, sulfur and salicylic acid are used in combination, but there are constant questions about human safety. Therefore, it is necessary to study a substance which is harmless to the human body and can suppress seborrheic dermatitis and dandruff.
일 측면에서, 본 발명의 목적은, 락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331266(기탁번호: KCCM11181P)의 신규한 용도를 제공하는 것이다.In one aspect, an object of the present invention is to provide a novel use of Lactobacillus plantarum APsulloc 331266 (accession number: KCCM 11181P).
다른 측면에서, 본 발명의 목적은, 락토바실러스 플란타룸 APsulloc 331266을 유효성분으로 함유하는 조성물을 이용하여 지루성 두피염 또는 비듬을 예방, 개선 또는 치료하는 것이다.In another aspect, the object of the present invention is to prevent, ameliorate, or treat seborrhoeic dermatitis or dandruff using a composition containing Lactobacillus plantarum APsulloc 331266 as an active ingredient.
일 측면에서, 본 발명은, 락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331266(기탁번호: KCCM11181P) 균주, 그 파쇄물, 그 배양액 또는 그 추출물을 유효성분으로 포함하는 항진균용 조성물을 제공한다.In one aspect, the present invention provides a composition for an antifungal agent comprising Lactobacillus plantarum APsulloc 331266 (accession number: KCCM11181P) strain, a lysate thereof, a culture thereof or an extract thereof as an active ingredient.
일 측면에 있어서, 본 발명의 락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331266 균주, 그 파쇄물, 그 배양액 또는 그 추출물을 유효성분으로 포함하는 조성물은, 지루성 두피염 또는 비듬을 유발시키는 말라세지아 속 진균에 대한 항진균력이 있으므로, 지루성 두피염 또는 비듬을 예방, 개선 또는 치료하는데 사용할 수 있다. 또한, 상기 조성물은, 세포 독성이 없고, 피부 자극을 유발하지 않아 인체에 무해하며, 염증성 사이토카인의 발현양을 낮추므로 염증 진정 효과도 있다.In one aspect, a composition comprising the Lactobacillus plantarum APsulloc 331266 strain of the present invention, a lysate thereof, a culture thereof, or an extract thereof as an active ingredient may be used as an effective ingredient for preventing or treating seborrheic dermatitis or dandruff in Malassezia genus Because of the antifungal activity against fungi, it can be used to prevent, ameliorate or treat seborrheic dermatitis or dandruff. In addition, the composition has no cytotoxicity, does not induce skin irritation, is harmless to the human body, and lowers the expression level of inflammatory cytokines.
도 1은, 디스크 확산법에 의해 락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331266 배양액의 말라세지아 퍼퍼(Malassezia furfur)에 대한 항진균력을 확인한 도이다.
도 2는, 락토바실러스 플란타룸 APsulloc 331266 배양액의 세포 독성을 확인한 도이다.
도 3은, 락토바실러스 플란타룸 APsulloc 331266 배양액의 피부 자극성 유무를 확인한 도이다.
도 4는, 락토바실러스 플란타룸 APsulloc 331266 배양액의 염증 억제 효과를 확인한 도이다.
도 5는, 락토바실러스 플란타룸 APsulloc 331266 배양액의 농도에 따른 말라세지아 퍼퍼(Malassezia furfur)에 대한 항진균력을 확인한 그래프이다.1 is a view showing antifungal activity against Malassezia furfur of a Lactobacillus plantarum APsulloc 331266 culture medium by a disk diffusion method.
FIG. 2 is a chart for confirming cytotoxicity of a Lactobacillus plantarum APsulloc 331266 culture medium. FIG.
Fig. 3 is a diagram showing the skin irritancy of Lactobacillus plantarum APsulloc 331266 culture. Fig.
Fig. 4 is a graph showing the inflammation inhibitory effect of the Lactobacillus plantarum APsulloc 331266 culture medium. Fig.
5 is a graph showing antifungal activity against Malassezia furfur according to the concentration of Lactobacillus plantarum APsulloc 331266 culture medium.
락토바실러스(Lactobacillus)는 대개 인간 또는 동물의 장관(Intestinal tract)에 존재하는 주요 유산균의 하나로 생리학적 활성에 대한 유리한 효과로 다양한 생균제(Probiotics)에 부가된다. 이 중 락토바실러스 플란타룸(Lactobacillus plantarum)은, 막대기 모양의 간균이며 그람양성균이다. 아라비노스, 글루코스, 프럭토스, 갈락토스, 말토스, 슈크로스, 덱스트란, 라피노스와 트레할로스 등을 발효시켜서 젖산을 생성한다. 주로 우유, 치즈, 버터, 케피어(kefir), 발효된 소시지, 발효된 감자, 곡물, 빵의 산성 반죽, 피클이나 김치와 같은 침채류, 토마토 등에서 분리되며, 자연계에서 가장 분포가 넓은 젖산균 중의 하나이다. 최근, 락토바실러스 플란타룸이 헬리코박터, 살모넬라, 에쉐리키아, 스타필로코커스, 칸디다 등의 병원성 균의 증식 또는 활성을 억제하는 물질을 함유하거나 배출한다는 연구가 상당수 진행된 바 있다. 그러나 락토바실러스 플란타룸을 이용하여 지루성 피부염, 두피염 및 비듬을 유발하는 말라세지아의 증식 또는 활성을 억제하고자 하는 연구는 전무하다. Lactobacillus bacteria (Lactobacillus) are usually added to a variety of probiotics (Probiotics) with favorable effects on the physiological activity as one of the main lactic acid bacteria present in the views of a human or animal (Intestinal tract). Among these, Lactobacillus plantarum is a rod-shaped bacterium and gram-positive bacteria. Lactic acid is produced by fermenting arabinose, glucose, fructose, galactose, maltose, sucrose, dextran, raffinose and trehalose. It is one of the most widely distributed lactic acid bacteria in nature, separated mainly from milk, cheese, butter, kefir, fermented sausages, fermented potatoes, grains, acid dough of bread, pickles and tomatoes such as pickles and kimchi . Recently, a lot of researches have been conducted to contain or release substances that inhibit the growth or activity of pathogenic bacteria such as Helicobacter, Salmonella, Escherichia, Staphylococcus, Candida, etc., in Lactobacillus plantarum. However, there have been no studies to inhibit proliferation or activity of malassezia causing seborrhoeic dermatitis, scalpitis and dandruff using Lactobacillus plantarum.
본 발명자들은, 제주 차나무(Camellia sinensis) 잎에서 분리한 락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331266 균주와 그 배양액이 지루성 피부염, 지루성 두피염 및 비듬을 유발하는 것으로 알려진 말라세지아(Malassezia sp.)에 대하여 항진균력이 있음을 발견하여, 본 발명을 완성하게 되었다.The present inventors have found that a strain of Lactobacillus plantarum APsulloc 331266 isolated from Jeju ( Camellia sinensis ) leaf and a culture thereof are effective against Malassezia sp., Which is known to cause seborrheic dermatitis, seborrheic dermatitis and dandruff. ), And thus the present invention has been completed.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은, 일 측면에서 락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331266(기탁번호: KCCM11181P) 균주, 그 파쇄물, 그 배양액 또는 그 추출물을 유효성분으로 포함하는 항진균용 조성물이다. In one aspect, the present invention is a composition for an antifungal agent comprising Lactobacillus plantarum APsulloc 331266 (accession number: KCCM11181P) strain, a lysate thereof, a culture thereof or an extract thereof as an active ingredient.
상기 균주는, 차나무(Camellia sinensis) 잎에서 분리한 균주로 락토바실러스 플란타룸(Lactobacillus plantarum)에 속한다. 구체적으로, APsulloc 331266은 차나무 잎을 차나무 잎 중량 대비 5 내지 15 중량%의 식염으로 절이는 단계; 절인 차나무 잎을 0.1% 내지 3%의 프락토 올리고당을 예로 들 수 있는 당용액과 혼합하여 25 내지 35에서 1 내지 5일간 배양하는 단계; 및 pH 5 미만으로 된 배양액을 취하여 25 내지 35 혐기 조건에서 1 내지 5일간 배양하는 단계를 포함하는 방법으로 분리할 수 있다. The strain is a strain isolated from the leaves of Camellia sinensis and belongs to Lactobacillus plantarum . Specifically, APsulloc 331266 includes the steps of ripening tea leaves with a salt of 5 to 15% by weight based on the weight of the tea leaves; Pickling the marinated tea leaves with a sugar solution, such as 0.1% to 3% fructooligosaccharide, and incubating at 25 to 35 for 1 to 5 days; And culturing the culture medium having a pH of less than 5, and culturing the culture medium for 1 to 5 days at 25 to 35 anaerobic conditions.
본 명세서에서, 상기 배양액 또는 그 추출물은, 균주, 예컨대, 락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331266를 배양하여 발생한 배양 산물을 함유하는 배양액 또는 그 배양액의 추출물을 의미할 수 있다. 배양액에는 균주 자체도 포함되어 있을 수 있다.In this specification, the culture broth or an extract thereof may mean a culture solution containing the culture product produced by culturing a strain, for example, Lactobacillus plantarum APsulloc 331266, or an extract of the culture solution. The culture medium may contain the strain itself.
상기와 같은 측면에서, 상기 항진균 대상인 균은 말라세지아(Malassezia sp.)일 수 있다. 말라세지아는, 피티로스포룸(Pityrosporum)이라고도 불리운다. 구체적으로, 상기 말라세지아는, 말라세지아 퍼퍼(Malassezia furfur), 말라세지아 글로보사(Malassezia globosa) 및 말라세지아 레스트릭타(Malassezia restricta)로 이루어진 군으로부터 선택된 하나 이상일 수 있다.In this aspect, the fungus of the antifungal agent may be Malassezia sp. Malasejia is also called Pityrosporum. Specifically, the Malassezia is Malassezia < RTI ID = 0.0 > furfur), dry years global Jia Bossa (Malassezia globosa), and do other tricks Les Jia three (Malassezia restricta ). < / RTI >
상기와 같은 측면에서, 상기 조성물은, 지루성 피부염 또는 비듬의 예방, 개선 또는 치료용 조성물일 수 있다. In the above aspect, the composition may be a composition for preventing, ameliorating or treating seborrheic dermatitis or dandruff.
상기와 같은 측면에서, 상기 지루성 피부염은 지루성 두피염일 수 있다.In the above aspect, the seborrheic dermatitis may be a seborrheic scalp salt.
구체적으로, 말라세지아 퍼퍼, 말라세지아 글로보사 및 말라세지아 레스트릭타는 지루성 피부염, 두피염 및 비듬을 유발하는 것으로 알려져 있으므로, 상기 균들의 증식, 생장을 억제하거나 상기 균들을 사멸시키면, 지루성 피부염, 두피염 및 비듬의 예방, 개선 또는 치료 효과를 기대할 수 있다.Specifically, it is known that Malasejia percha, Malasejia globosa and Malasejiaestrica cause seborrheic dermatitis, scalpitis and dandruff. Therefore, if the growth and growth of the above-mentioned fungi are suppressed or the fungi are killed, Dermatitis, scalpitis and dandruff can be expected.
상기와 같은 측면에서, 상기 락토바실러스 플란타룸 APsulloc 331266(기탁번호: KCCM11181P) 균주, 그 파쇄물, 그 배양액 또는 그 추출물은, 조성물 총 중량을 기준으로, 0.01중량% 내지 10중량%로 포함될 수 있다. 일 구체예에서, 상기 락토바실러스 플란타룸 APsulloc 331266(기탁번호: KCCM11181P) 균주, 그 파쇄물, 그 배양액 또는 그 추출물은, 조성물 총 중량을 기준으로, 0.1중량%~5중량%로 포함될 수 있다. 상기와 같은 측면에서, 상기 락토바실러스 플란타룸 APsulloc 331266 균주, 그 파쇄물, 그 배양액 또는 그 추출물은, 조성물 총 중량을 기준으로, 0.001중량% 이상, 0.005중량% 이상, 0.01중량% 이상, 0.1중량% 이상, 1중량% 이상, 3중량% 이상, 5중량% 이상, 7중량% 이상, 9중량% 이상, 10중량% 이상 또는 11중량% 이상 포함될 수 있고, 11중량% 이하, 10중량% 이하, 9중량% 이하, 7중량% 이하, 5중량% 이하, 3중량% 이하, 1중량% 이하, 0.1중량% 이하, 0.005중량% 이하 또는 0.003중량% 이하로 포함될 수 있다. In the above aspect, the Lactobacillus plantarum APsulloc 331266 (accession number: KCCM11181P) strain, the lysate thereof, the culture or the extract thereof may be contained in an amount of 0.01 to 10% by weight based on the total weight of the composition . In one embodiment, the Lactobacillus plantarum APsulloc 331266 (accession number: KCCM11181P) strain, the lysate thereof, the culture or the extract thereof may be contained in an amount of 0.1% to 5% by weight based on the total weight of the composition. In the above aspect, the Lactobacillus plantarum APsulloc 331266 strain, the lysate thereof, the culture solution thereof or the extract thereof may be added in an amount of 0.001 wt% or more, 0.005 wt% or more, 0.01 wt% or more, 0.1 wt% At least 1% by weight, at least 3% by weight, at least 5% by weight, at least 7% by weight, at least 9% by weight, at least 10% by weight or at least 11% by weight, , 9 wt% or less, 7 wt% or less, 5 wt% or less, 3 wt% or less, 1 wt% or less, 0.1 wt% or less, 0.005 wt% or less or 0.003 wt% or less.
상기와 같은 측면에서, 상기 조성물은, 약학적 조성물, 화장료 조성물 또는 건강 식품 조성물일 수 있다.In this aspect, the composition may be a pharmaceutical composition, a cosmetic composition or a health food composition.
상기 화장료 조성물은 국소 적용에 적합한 모든 제형으로 제공될 수 있다. 예를 들면, 액, 수상에 유상을 분산시켜 얻은 에멀젼, 유상에 수상을 분산시켜 얻은 에멀젼, 현탁액, 고체, 겔, 분말, 페이스트, 포말(foam) 또는 에어로졸 조성물의 제형으로 제공될 수 있다. 이러한 제형의 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다.The cosmetic composition may be provided in all formulations suitable for topical application. For example, it may be provided as a liquid, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an oil phase in water, a suspension, a solid, a gel, a powder, a paste, a foam or an aerosol composition. Compositions of such formulations may be prepared according to conventional methods in the art.
상기 화장료 조성물은 상기한 물질 이외에 주 효과를 손상시키지 않는 범위 내에서, 바람직하게는 주 효과에 상승 효과를 줄 수 있는 다른 성분들을 함유할 수 있다. 본 발명에 따른 화장료 조성물은 비타민, 고분자 펩티드, 분자 다당 및 스핑고 지질로 이루어진 군에서 선택된 물질을 포함할 수 있다. 또한 본 발명에 따른 화장료 조성물은 보습제, 에몰리언트제, 계면 활성제, 자외선 흡수제, 방부제, 살균제, 산화 방지제, pH 조정제, 유기 및 무기 안료, 향료, 냉감제 또는 제한(制汗)제를 포함할 수 있다. 상기 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 선정 가능하며, 그 배합량은 조성물 전체 중량을 기준으로 0.01~5 중량%, 구체적으로 0.01~3 중량%일 수 있다.The cosmetic composition may contain, in addition to the above-mentioned substances, other ingredients which can give synergistic effects to the main effect, so long as they do not impair the main effect. The cosmetic composition according to the present invention may include a material selected from the group consisting of vitamins, high molecular peptides, molecular polysaccharides and sphingolipids. The cosmetic composition according to the present invention may also contain a moisturizing agent, an emollient agent, a surfactant, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a pH adjuster, an organic and inorganic pigment, a fragrance, . The blending amount of the above components can be easily selected by those skilled in the art within a range not to impair the objects and effects of the present invention. The blending amount thereof can be 0.01 to 5% by weight, specifically 0.01 to 3% by weight based on the total weight of the composition have.
상기와 같은 측면에서, 상기 약학적 조성물 또는 화장료 조성물은 피부 외용제 조성물일 수 있다. 예컨대, 크림, 연고일 수 있다.In the above aspect, the pharmaceutical composition or cosmetic composition may be a composition for external application to the skin. For example, it may be cream or ointment.
상기 식품 조성물은 건강 식품 조성물일 수 있으며, 다(茶)류, 유제품류, 김치류, 양조 식품류를 예로 들 수 있는 발효가 필요한 발효 식품 조성물일 수 있다. 상기 식품 조성물의 제형은 특별히 한정되지 않으나, 예를 들어, 정제, 환제, 연질 및 경질 캅셀제, 과립제, 드링크제, 캐러멜, 다이어트바, 티백 등으로 제형화될 수 있다. 각 제형의 식품 조성물은 유효 성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다. 상기 유효 성분의 투여량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 락토바실러스 플란타룸 105내지 1013CFU/일, 보다 구체적으로는 106 내지 1010 CFU/일이 될 수 있으나, 이에 제한되지 않으며, 투여하고자 하는 대상의 연령, 건강 상태, 합병증 등의 다양한 요인에 따라 달라질 수 있다.The food composition may be a health food composition, and may be a fermented food composition requiring fermentation, such as tea, dairy, kimchi, and brewed foods. The formulation of the food composition is not particularly limited, but may be formulated into tablets, pills, soft and hard capsules, granules, drinks, caramels, diet bars, tea bags and the like. The food composition of each formulation can be blended with the ingredients commonly used in the field in addition to the active ingredient without difficulty by those skilled in the art depending on the purpose of formulation or use, and synergistic effect can be obtained when the composition is applied simultaneously with other ingredients. Determination of the dosage of the active ingredient is within the level of ordinary skill in the art, and its daily dose is, for example, 10 5 to 10 13 CFU / day, more specifically 10 6 to 10 10 CFU / day for Lactobacillus plantarum But may vary depending on various factors such as the age, health condition, complications, etc. of the subject to be administered.
이하, 본 발명을 하기의 실시예 및 실험예를 통하여 설명한다. 하기 실시예 및 실험예는 본 발명에 대한 이해를 돕기 위해 예시의 목적으로만 제공된 것일 뿐 본 발명의 범주 및 범위가 그에 의해 제한되는 것은 아니다.Hereinafter, the present invention will be described with reference to the following examples and experimental examples. The following Examples and Experimental Examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, but the scope and scope of the present invention are not limited thereto.
[실시예 1]차나무 잎에서 분리한 락토바실러스 플란타룸 APsulloc 331266의 준비[Example 1] Preparation of Lactobacillus planta APsulloc 331266 isolated from tea leaves
[실시예 1-1]락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331266의 분리[Example 1-1] Isolation of Lactobacillus plantarum APsulloc 331266
아래에서 본 발명의 일 실시예에 따른 유산균 중 락토바실러스 플란타룸 APsulloc 331266의 분리 과정에 대해 설명한다.Hereinafter, the separation process of Lactobacillus plantarum APsulloc 331266 among lactic acid bacteria according to an embodiment of the present invention will be described.
차나무 잎 200g을 1차 증류수에 2회 세척하여 이물질을 제거하였다. 세척한 차나무 잎의 물기를 털어내고 차나무 잎 중량의 8%에 해당하는 식염과 혼합한 후 3시간 동안 실온에 방치하였다. 식염에 절여진 차나무 잎을 1% 프락토 올리고당 용액 1000 mL에 혼합한 후 3일간 32 인큐베이터에서 배양하였다. 3일 후 배양액의 pH가 5 미만으로 떨어졌는지 확인하고 pH 5 미만인 경우 이를 취해 디프코 락토바실리 MRS 아가 (Difco Lactobacilli MRS Agar®) 배지에 배양하였다. 이때 배양은 32℃, 혐기 조건의 챔버에서 2일간 배양한 후 백색 집락을 보이는 콜로니를 취했다.200 g of tea leaves were washed twice with primary distilled water to remove foreign matter. The water from the washed tea leaves was bled out and mixed with the salt equivalent to 8% of the weight of the tea leaves and left at room temperature for 3 hours. The edible tea leaves were mixed in 1000 mL of 1% fructooligosaccharide solution and cultured in 32 incubator for 3 days. After 3 days, it was confirmed whether the pH of the culture broth was lowered to less than 5. When the pH was less than 5, it was taken and cultured in Difco Lactobacilli MRS Agar (R) medium. At this time, the culture was carried out in a chamber of anaerobic condition at 32 ° C for 2 days, and then a colony showing white colonies was taken.
위와 같은 방법으로 락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331266을 차나무 잎으로부터 분리하였다. Lactobacillus plantarum APsulloc 331266 was isolated from tea leaves in the same manner as above.
[실시예 1-2] 락토바실러스 플란타룸 APsulloc 331266 배양액의 제조[Example 1-2] Preparation of Lactobacillus flutarium APsulloc 331266 culture medium
실시예 1-1에서 분리 및 동정한 락토바실러스 플란타룸 APsulloc 331266을 배지(MRS Broth)에서 37℃ 환경에서 24시간 동안 배양하였다. 이 락토바실러스 플란타룸 APsulloc 331266은 탈지유(Skim milk)에 10중량%로 크라이오튜브(Cryotube)에서 보관한 것을 접종한 것이다. 액체 배지 내 균수가 5 X 108 ~ 1 X 109 가 되었을 때, 4℃에서, 4000 rpm 원심 분리를 통하여 영양세포를 제거하고, 포어사이즈가 0.2 mm인 실린지 필터링을 통해 기타 부유물을 제거하였다.Lactobacillus plantarum APsulloc 331266 isolated and identified in Example 1-1 was cultured in a medium (MRS Broth) for 24 hours at 37 ° C. The Lactobacillus plantarum APsulloc 331266 was inoculated with 10% by weight of skim milk stored in a cryotube. When the number of bacteria in the liquid medium reached 5 × 10 8 to 1 × 10 9 , the nutrient cells were removed by centrifugation at 4000 rpm at 4 ° C. and other floating matters were removed by syringe filtration with a pore size of 0.2 mm .
[실험예 1-1] 항진균력의 측정[Experimental Example 1-1] Measurement of antifungal activity
락토바실러스 플란타룸 APsulloc 331266 균주의 배양액의 항진균력을 측정하기 위하여 Agar well diffusion assay를 실시하였다. 구체적으로, 90 mm 플라스틱 평판 가운데에 페니실린더를 세우고 멸균된 Agar를 20 mL 부어 굳혔다. MLNA 배지에 말라세지아(Malassezia sp.)를 5 X 108 내지 1 X 109 cell/mL 농도로 접종하고, 굳은 Agar 위에 5 mL을 붓고 굳혔다. 상기 두 겹의 배지가 모두 굳으면 페니실린더를 조심스럽게 제거하고 생긴 홀(Hall)에 미량(약 50 - 100 uL)의 Agar를 채워 넣어 웰을 만들었다. 그 후, 실시예 1-2에서 제조된 배양액이 웰을 가득 채울 때까지 채우고 플레이트의 뚜껑을 덮은 후, 37℃에서 3일 배양하여 억제대의 지름을 자로 재어 결과를 판독하였다. 그 결과는 도 1에 나타나 있다.Agar well diffusion assay was performed to measure the antifungal activity of Lactobacillus plantarum APsulloc 331266. Specifically, a penicillin disc was placed in a 90 mm plastic plate, and 20 mL of sterilized Agar was poured and hardened. Malassezia sp. Was inoculated to the MLNA medium at a concentration of 5 × 10 8 to 1 × 10 9 cells / mL, and 5 mL was poured over the hard agar and allowed to harden. When the two-fold culture medium was completely hardened, the penicillin was carefully removed and a small amount (about 50-100 uL) of Agar was filled into the formed holes to form wells. Thereafter, the culture solution prepared in Example 1-2 was filled until the wells were filled, the plate was covered with the lid, and the plate was incubated at 37 DEG C for 3 days. The results are shown in Fig.
[실험예 1-2] 항진균력의 측정[Experimental Example 1-2] Measurement of Antifungal Activity
락토바실러스 플란타룸 APsulloc 331266 균주의 배양액의 항진균력을 측정하기 위하여 시료 농도와 배양 시간에 따른 말라세지아 퍼퍼(Malassezia furfur)의 억제 정도를 Agar plate counting을 통하여 확인하였다.In order to measure the antifungal activity of Lactobacillus plantarum APsulloc 331266, the inhibitory effect of Malassezia furfur on the sample concentration and incubation time was confirmed by agar plate counting.
4개의 50 mL 튜브에 락토바실러스 플란타룸 APsulloc 331266 균주 배양액이 0%, 10%, 20%, 30%가 되도록 시료 농도를 구배하였다. 구체적으로는 MLNA 배지를 21 mL 부은 후, 1) MRS 배지 9 mL, 2) MRS 배지 6 mL과 배양액 3 mL, 3) MRS 배지 3 mL과 배양액 6 mL, 4) 배양액 9 mL을 추가로 혼합하여 시료 농도를 정확히 구배할 수 있다. 각 튜브에 말라세지아 퍼퍼를 1 X 106 cell/mL 농도가 되도록 접종 후 35 인큐베이터에서 배양하였다. 배양 즉시, 24 시간 후, 48 시간 후, 72 시간 후 각 시험 샘플로부터 1 mL를 취하여 생리식염수에 1/10 연속 희석을 실시하고 이를 MLNA agar에 스프레딩한 후 35에서 3일 배양하여 생성된 콜로니 수를 확인하므로써 생균수 결과를 판독하였다(도 5). 그 결과, 락토바실러스 플란타룸 APsulloc 331266의 배양액은 농도가 증가할수록 말라세지아 퍼퍼에 대한 항진균력이 증가함을 알수 있었다.The sample concentration was graded so that the culture broth of Lactobacillus plantarum APsulloc 331266 was 0%, 10%, 20%, and 30% in four 50-mL tubes. Specifically, 1 mL of MRS medium, 6 mL of MRS medium, 3 mL of MRS medium, 3 mL of MRS medium, 6 mL of culture medium and 9 mL of culture medium were further mixed The sample concentration can be accurately graded. Malassezia pupae were inoculated into each tube at a concentration of 1 × 10 6 cells / mL and then cultured in a 35 incubator. Immediately after culturing, 1 mL of each test sample was taken after 24 hours, 48 hours, and 72 hours, and 1/10 serial dilution was performed in physiological saline, spread on MLNA agar, and cultured for 35 days for 3 days. The number of living cells was read by confirming the number (Fig. 5). As a result, it was found that the antifungal activity against Lactobacillus plantarum APsulloc 331266 increased with increasing concentration.
[실험예 2] 세포 독성 측정[Experimental Example 2] Cytotoxicity measurement
실시예 1-2의 락토바실러스 플란타룸 APsulloc 331266 균주 배양액의 세포독성 유무를 확인하기 위하여 하기 실험을 수행하였다. 인간 각질 형성 세포주인 HaCaT 세포(Invitrogen)를 96 웰 플레이트에 2X104 cells/well 농도로 부착시키고, FBS를 포함하는 DMEM 배지에서 24시간 배양하였다. PBS(phosphate buffered saline)로 인간 각질 형성 세포를 세척한 후 락토바실러스 플란타룸 APsulloc 331266의 배양액을 농도별(1%, 2%, 5%)로 처리하여 24시간 동안 반응시켰다. 그 후, 세포 배양액 100 ㎕ 당 10 ㎕의 WST-1 용액을 넣고 30분 내지 2시간 동안 37℃에서 반응 시키고 450 nm에서 흡광도를 측정하였다. 흡광도는 살아있는 세포 수에 비례한다. 무처리군의 흡광도를 100%로 하였을 때 락토바실러스 플란타룸 APsulloc 331266의 배양액을 농도별로 처리하였을 때의 흡광도를 상대적으로 비교하였다(도2). 그 결과, 락토바실러스 플란타룸 APsulloc 331266의 배양액은 세포 독성이 없음을 알 수 있었다.The following experiment was conducted to confirm the cytotoxicity of the Lactobacillus plantarum APsulloc 331266 culture medium of Example 1-2. HaCaT cells (Invitrogen), a human keratinocyte cell line, were attached to a 96-well plate at a concentration of 2 × 10 4 cells / well and cultured in DMEM medium containing FBS for 24 hours. Human keratinocytes were washed with PBS (phosphate buffered saline) and treated with Lactobacillus plantarum APsulloc 331266 (1%, 2%, 5%) for 24 hours. Thereafter, 10 占 퐇 of WST-1 solution was added per 100 占 of the cell culture solution, reacted at 37 占 폚 for 30 minutes to 2 hours, and the absorbance at 450 nm was measured. Absorbance is proportional to the number of living cells. When the absorbance of the untreated group was taken as 100%, the absorbance of the culture solution of Lactobacillus plantarum APsulloc 331266 was comparatively compared (FIG. 2). As a result, it was found that the culture solution of Lactobacillus plantarum APsulloc 331266 was not cytotoxic.
[실험예 3] 피부 자극성 유무 확인[Experimental Example 3] Confirmation of skin irritancy
상기 실시예 1-2의 배양액이 피부에 자극을 일으키는지 확인하기 위해 하기 실험을 수행하였다. 인간 각질 형성 세포 라인 HaCaT 세포를 96 well cell culture plate에 2X104 cells/well 농도로 부착시키고 FBS를 포함하는 DMEM 배지에서 24시간 배양하여 준비하였다. PBS(phosphate buffered saline)로 세포를 세척한 후 DMEM 배지 및 10μM PMA(12-ο-tetradecanoylphorbol-13-acetate) 또는 상기 실시예 1-2의 배양액을 20% 농도로 처리하여 세포에서 분비되는 염증성 사이토카인인 IL-1α와 TNF-α의 양을 비교하였다. 그 결과, 락토바실러스 플란타룸 APsulloc 331266 배양액은 피부 자극성이 없음을 알 수 있었다(도 3).The following experiment was conducted to confirm whether the culture medium of Example 1-2 was stimulating the skin. Human keratinocyte line HaCaT cells were attached to a 96 well cell culture plate at a concentration of 2 × 10 4 cells / well and cultured in DMEM medium containing FBS for 24 hours. Cells were washed with PBS (phosphate buffered saline) and treated with DMEM medium and 10 μM PMA (12-o-tetradecanoylphorbol-13-acetate) or the culture medium of Example 1-2 at a concentration of 20% The amounts of IL-1α and TNF-α, which are kinases, were compared. As a result, it was found that the culture of Lactobacillus plantarum APsulloc 331266 had no skin irritation (Fig. 3).
[실험예 4] 염증 억제 효과 확인 [Experimental Example 4] Confirmation of inflammation inhibitory effect
상기 실시예 1-2의 배양액이 염증 억제 효과가 있는지 확인하기 위해 하기 실험을 수행하였다. 인간 각질 형성 세포 라인 HaCaT 세포를 96 well cell culture plate에 2X104 cells/well 농도로 부착시키고 FBS를 포함하는 DMEM 배지에서 24시간 배양하여 준비하였다. PBS(phosphate buffered saline)로 세포를 세척한 후 DMEM 배지 및 10μM PMA(12-ο-tetradecanoylphorbol-13-acetate)를 처리하여 세포에 염증성 사이토카인의 분비를 유도하였다. 그 후, 락토바실러스 플란타룸 APsulloc 331266의 배양액을 처리하고 염증성 사이토카인의 분비량을 확인하였다. 그 결과, 락토바실러스 플란타룸 APsulloc 331266의 배양액을 처리한 군에서 IL-1α의 분비량이 감소하는 것을 확인하였고, 상기 균주 배양액이 염증 억제 효과가 있음을 알 수 있었다(도 4). The following experiment was conducted to confirm whether the culture solution of Example 1-2 had an inflammation-inhibiting effect. Human keratinocyte line HaCaT cells were attached to a 96 well cell culture plate at a concentration of 2 × 10 4 cells / well and cultured in DMEM medium containing FBS for 24 hours. Cells were washed with PBS (phosphate buffered saline) and treated with DMEM medium and 10 μM PMA (12-ο-tetradecanoylphorbol-13-acetate) to induce the secretion of inflammatory cytokines into the cells. After that, the culture medium of Lactobacillus plantarum APsulloc 331266 was treated and the secretion amount of inflammatory cytokine was confirmed. As a result, it was confirmed that the secretion amount of IL-1α was decreased in the group treated with the culture solution of Lactobacillus plantarum APsulloc 331266, and the culture medium of the strain showed an inflammation-inhibiting effect (FIG. 4).
본 발명의 일 실시예에 따른 조성물의 제형예를 아래에서 설명하나, 다른 여러 가지 제형으로도 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다Formulation examples of compositions according to one embodiment of the present invention are described below, but may be applied to various other formulations, which are not intended to be limiting but merely illustrative of the present invention
[제형예 1] 영양화장수[Formulation Example 1] Nutritional lotion
하기 표 1에 기재된 조성에 따라 통상적인 방법으로 영양화장수를 제조하였다.Nutrition lotion was prepared according to a conventional method according to the composition shown in Table 1 below.
[제형예 2] 영양로션[Formulation Example 2] Nutrition lotion
하기 표 2에 기재된 조성에 따라 통상적인 방법으로 영양로션을 제조할 수 있다.Nutrition lotions can be prepared in a conventional manner according to the composition shown in Table 2 below.
[제형예 3] 영양크림[Formulation Example 3] Nourishing cream
하기 표 3에 기재된 조성에 따라 통상적인 방법으로 영양크림을 제조할 수 있다.Nutrition creams can be prepared in a conventional manner according to the composition shown in Table 3 below.
[제형예 4] 헤어 팩[Formulation Example 4] Hair pack
하기 표 4에 기재된 조성에 따라 통상적인 방법으로 팩을 제조할 수 있다.The pack can be manufactured in a conventional manner according to the composition shown in Table 4 below.
[제형예 5] 샴푸[Formulation Example 5] Shampoo
하기 표 5에 기재된 조성에 따라 통상적인 방법으로 샴푸를 제조할 수 있다.The shampoos can be prepared by a conventional method according to the composition shown in Table 5 below.
[제형예 6] 린스[Formulation Example 6] Rinse
하기 표 6에 기재된 조성에 따라 통상적인 방법으로 린스를 제조할 수 있다.Rinse can be prepared according to a conventional method according to the composition shown in Table 6 below.
[제형예 7] 헤어 스프레이[Formulation Example 7] Hair spray
하기 표 7에 기재된 조성에 따라 통상적인 방법으로 스프레이를 제조할 수 있다.Spray can be prepared by a conventional method according to the composition shown in Table 7 below.
[제형예 8] 헤어토닉[Formulation Example 8] Hair tonic
하기 표 8에 기재된 조성에 따라 통상적인 방법으로 헤어토닉을 제조할 수 있다.Hair tonics can be prepared by a conventional method according to the composition shown in Table 8 below.
상기 락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331266은 2011년 3월 28일 한국미생물보존센터(Korean Culture Center of Microorganisms)에 미생물 기탁번호 KCCM11181P로 기탁하였다.The Lactobacillus plantarum APsulloc 331266 was deposited with the Korean Culture Center of Microorganisms on March 28, 2011 as microorganism deposit number KCCM 11181P.
Claims (8)
상기 항진균 대상인 균은, 말라세지아(Malassezia sp.)인, 항진균용 조성물.The method according to claim 1,
Wherein the bacterium which is a target of the antifungal agent is Malassezia sp.
상기 말레세지아는,
말라세지아 퍼퍼(Malassezia furfur), 말라세지아 글로보사(Malassezia globosa) 및 말라세지아 레스트릭타(Malassezia restricta)로 이루어진 군으로부터 선택된 하나 이상인, 항진균용 조성물.3. The method of claim 2,
The above-
Malassezia furfur), dry years global Jia Bossa (Malassezia globosa), and do other tricks Les Jia three (Malassezia restricta ). < / RTI >
상기 조성물은, 지루성 피부염 또는 비듬의 예방, 개선 또는 치료용인, 항진균용 조성물.The method according to claim 1,
Wherein said composition is for preventing, ameliorating or treating seborrheic dermatitis or dandruff.
상기 지루성 피부염은, 지루성 두피염인, 항진균용 조성물. 5. The method of claim 4,
Wherein said seborrheic dermatitis is a seborrheic dermatitis.
상기 락토바실러스 플란타룸 APsulloc 331266(기탁번호: KCCM11181P) 균주, 그 파쇄물, 그 배양액 또는 그 추출물은,
조성물 총 중량을 기준으로, 0.01중량% 내지 10중량%로 포함되는, 항진균용 조성물.The method according to claim 1,
The Lactobacillus plantarum APsulloc 331266 (Accession No .: KCCM11181P) strain, the lysate thereof, the culture or the extract thereof,
Wherein the composition comprises from 0.01% to 10% by weight, based on the total weight of the composition.
상기 락토바실러스 플란타룸 APsulloc 331266(기탁번호: KCCM11181P) 균주, 그 파쇄물, 그 배양액 또는 그 추출물은,
조성물 총 중량을 기준으로, 0.1중량% 내지 5중량%로 포함되는, 항진균용 조성물.The method according to claim 1,
The Lactobacillus plantarum APsulloc 331266 (Accession No .: KCCM11181P) strain, the lysate thereof, the culture or the extract thereof,
Wherein the composition comprises from 0.1% to 5% by weight, based on the total weight of the composition.
상기 조성물은,
화장료 조성물 또는 건강 식품 조성물인, 항진균용 조성물.The method according to claim 1,
The composition may comprise,
A composition for an antifungal agent, which is a cosmetic composition or a health food composition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160011621 | 2016-01-29 | ||
| KR1020160011621 | 2016-01-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170090997A true KR20170090997A (en) | 2017-08-08 |
| KR102623439B1 KR102623439B1 (en) | 2024-01-11 |
Family
ID=59652994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160182201A KR102623439B1 (en) | 2016-01-29 | 2016-12-29 | Anti-fungal composition comprising lactobacillus plantarum |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102623439B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190002079A (en) * | 2017-06-29 | 2019-01-08 | (주)아모레퍼시픽 | Anti-aging composition comprising extracellular vesicles derived from lactic acid bacteria |
| KR101966184B1 (en) | 2018-09-21 | 2019-04-05 | 주식회사 제이투케이바이오 | NTI-FUNGAL Cosmetic Composition of Malassezia furfur |
| WO2020208253A1 (en) * | 2019-04-12 | 2020-10-15 | Biodermic Health & Beauty Gmbh & Co. Kg | Composition for a topical application on the skin |
| KR102606325B1 (en) * | 2022-11-15 | 2023-12-04 | 주식회사 큐옴바이오 | Composition for antibacterial and skin disease improvement against skin harmful bacteria containing lactobacillus plantarum q1 strain |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100333424B1 (en) | 1994-04-07 | 2002-10-25 | 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 | Anti-dandruff shampoo formulation |
| KR20130000001A (en) * | 2011-06-10 | 2013-01-02 | (주)아모레퍼시픽 | New lactobacillus plantarum isolated from tea leaf |
-
2016
- 2016-12-29 KR KR1020160182201A patent/KR102623439B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100333424B1 (en) | 1994-04-07 | 2002-10-25 | 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 | Anti-dandruff shampoo formulation |
| KR20130000001A (en) * | 2011-06-10 | 2013-01-02 | (주)아모레퍼시픽 | New lactobacillus plantarum isolated from tea leaf |
Non-Patent Citations (1)
| Title |
|---|
| 양은주 et al., Kor. J. Microbiol. Biotechnol. 2008, 36, 276-284(2008)* * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190002079A (en) * | 2017-06-29 | 2019-01-08 | (주)아모레퍼시픽 | Anti-aging composition comprising extracellular vesicles derived from lactic acid bacteria |
| KR101966184B1 (en) | 2018-09-21 | 2019-04-05 | 주식회사 제이투케이바이오 | NTI-FUNGAL Cosmetic Composition of Malassezia furfur |
| WO2020208253A1 (en) * | 2019-04-12 | 2020-10-15 | Biodermic Health & Beauty Gmbh & Co. Kg | Composition for a topical application on the skin |
| KR102606325B1 (en) * | 2022-11-15 | 2023-12-04 | 주식회사 큐옴바이오 | Composition for antibacterial and skin disease improvement against skin harmful bacteria containing lactobacillus plantarum q1 strain |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102623439B1 (en) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102194315B1 (en) | Antioxidant or skin microbiome balance cosmetic composition comprising centella asiatica fermented extract fermented by inoculating lactobacillus rhamnosus strain | |
| KR102356423B1 (en) | Composition Comprising Complex Strain with Anti-microbial, Skin Moisturizing, Anti-atopy, Skin Barrier, and Anti-wrinkle Property as Active Ingredient | |
| US9675650B2 (en) | Composition for removing keratinous skin material comprising green tea Lactobacillus | |
| KR102623439B1 (en) | Anti-fungal composition comprising lactobacillus plantarum | |
| KR101864409B1 (en) | Antibacterial or antifungal composition comprising oriental medicine extract and microbial ferment extract as an active ingredient | |
| KR102149973B1 (en) | Antimicrobial and Antifungal Composition Comprising Eugenol and Gallic Acid as Active Ingredient | |
| CN104958248A (en) | Biological antibacterial composition and application of biological antibacterial composition in cosmetics | |
| KR102610933B1 (en) | Composition for hair or scalp comprising lysate of Lactobacillus plantarum | |
| KR20170027685A (en) | Anti-aging Composition Including Dendranthema zawadskii Extract, and Cosmetic Composition for young face by Anti-aging, Skin-lifting and Anti-wrinkle | |
| KR102056916B1 (en) | Novel Lactobacillus bulgaricus UBC-U27 with anti-skin aging or anti-wrinkle activity, and compositions using the same | |
| KR20190036298A (en) | A composition for improving inflammatory skin disease containing evergreen woody species | |
| KR102059392B1 (en) | Antimicrobial and Antifungal Composition Containing Clove, Hibiscus, and Coconut Extract Complex as Active Ingredient | |
| KR102247810B1 (en) | Composition Comprising Mixed Culture Strain of Lactobacillus sp. SDCM 1003 and SDCM 1105, Culture Fluid, or Culture Fluid Extract thereof as Active Ingredient | |
| KR20220004328A (en) | Composition for maintaining the balance of microbiome in the skin comprising hampseed oil | |
| CN114984063B (en) | Skin external composition and functional food composition | |
| KR20170038582A (en) | Antiseptic containing caprylic/capric glycerides and composition for skin external application containing thereof | |
| KR102610934B1 (en) | Composition for hair or scalp comprising lysate of Lactobacillus sakei | |
| KR20190006285A (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
| KR20190050357A (en) | Composition for improving microbial flora containing extract of Rosae Multiflorae fructus | |
| KR20220094565A (en) | Antibacterial composition containing extract or fractions of Prunus pendula for. ascendens | |
| KR102194314B1 (en) | Antioxidant or skin microbiome balance cosmetic composition comprising green tea fermented extract fermented by inoculating lactobacillus rhamnosus strain | |
| KR102244812B1 (en) | Composition Comprising Mixed Culture Strain of Lactobacillus plantarum subsp. plantarum SDCM 1002 and Saccharomyce cerevisiae SDCM 3017, Culture Fluid, or Culture Fluid Extract thereof as Active Ingredient | |
| KR102066821B1 (en) | Natural Complex Cosmetic Preservative Composition | |
| KR101436923B1 (en) | Antibacterial oral composition containg cirsium sp exctract | |
| KR102196276B1 (en) | Probiotic composition comprising green tea fermented extract having antibacterial activity against acne-causing resident skin flora and antioxidant efficacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |